0001209191-21-010362.txt : 20210212
0001209191-21-010362.hdr.sgml : 20210212
20210212175627
ACCESSION NUMBER: 0001209191-21-010362
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210210
FILED AS OF DATE: 20210212
DATE AS OF CHANGE: 20210212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VERNON W ANTHONY
CENTRAL INDEX KEY: 0001369091
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39351
FILM NUMBER: 21630371
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvation Bio Inc.
CENTRAL INDEX KEY: 0001811063
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 850862255
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 754-3517
MAIL ADDRESS:
STREET 1: 357 TEHAMA STREET, FLOOR 3
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
FORMER COMPANY:
FORMER CONFORMED NAME: Panacea Acquisition Corp
DATE OF NAME CHANGE: 20200430
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-10
0
0001811063
Nuvation Bio Inc.
NUVB
0001369091
VERNON W ANTHONY
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401
NEW YORK
NY
10036
1
0
0
0
Class A Common Stock
2020-02-10
4
A
0
254100
A
254100
D
Class A Common Stock
2020-02-10
4
A
0
50000
10.00
A
304100
D
Stock Option (Right to Buy)
4.60
2021-02-10
4
A
0
51703
A
2030-10-04
Class A Common Stock
51703
51703
D
Stock Option (Right to Buy)
1.74
2021-02-10
4
A
0
187658
A
2030-01-21
Class A Common Stock
187658
187658
D
Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer").
On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors.
Options vest in 48 equal monthly installments from October 5, 2020.
Received in exchange for an option to purchase 51,703 shares of Legacy Nuvation Class A Common Stock.
Options vest in 48 equal monthly installments from July 17, 2019.
Received in exchange for an option to purchase 187,658 shares of Legacy Nuvation Class A Common Stock.
W. Anthony Vernon, by /s/ Ron A. Metzger, Attorney-in-Fact
2021-02-12